131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) | MicrobiomeTrials← Back to trialsNCT07015684
131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-04-28Est. Completion: 2030-03-12
Enrollment target: 24 participants Locations- Columbia University Irving Medical Center, New York, New York, United States
Other microbiome trials you might be interested in
Sickle Cell Disease (SCD)Invasive Bacterial Infections
Children with sickle cell disease are at high risk of invasive bacterial infections, which may lead to serious complicat…
Argenteuil, FranceEst. completion Jul 15, 2027
Sickle Cell Disease
The purpose of this clinical trial is to evaluate the performance of the sickle cell disease (SCD) electronic diary in p…
Hollywood, United StatesCompleted Jun 24, 2024